Schering-Plough transfers products in European market
Kenilworth, N.J. -- Schering-Plough Corp announced last month that it was closing on its transfer of certain products to Pfizer Animal Health.
Kenilworth, N.J.
-- Schering-Plough Corp announced last month that it was closing on its transfer of certain products to Pfizer Animal Health.
The transfers were requested by the European Commission as part of an October 2007 clearance of the acquisition of Oraganon BioSciences N.V. by Pfizer.
Products transferred to Pfizer in the European market include products from Schering-Plough's parasiticide, swine E. coli vaccine, ruminant clostridia vaccine, equine influenza vaccine, ruminant neonatal vaccine, anti-inflammatory companion animal/insulin and companion animal/euthanasia and rabies vaccine franchises, according to Schering-Plough.
Schering-Plough still will be able to market those items outside of the European market, according to the company.
Newsletter
From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.
FDA approves oral drug for broad canine protection against parasites
October 7th 2024Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More
